Trial · NCT07479693
Comparison of Hyaluronic Acid, Injectable Platelet-Rich Fibrin, and Prolotherapy in TMJ Arthrocentesis
NCT07479693, Not applicable, Completed, Ondokuz Mayıs University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Hyaluronic Acid, Injectable Platelet-Rich Fibrin, and Prolotherapy in TMJ Arthrocentesis. Trials, record NCT07479693. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07479693
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Hyaluronic Acid, Injectable Platelet-Rich Fibrin, and Prolotherapy in TMJ Arthrocentesis
- NCT number
- NCT07479693
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 36 participants, actual
- Lead sponsor
- Ondokuz Mayıs University
- Conditions
- Temporomandibular Joint Pain, Arthrocentesis
- Interventions
- Temporomandibular Joint Arthrocentesis, Hyaluronic Acid (Orthovisc), Injectable Platelet-Rich Fibrin (i-PRF), Dextrose prolotherapy (DPT)
- First posted
- 2026-03-18
- Last updated
- 2026-03-18
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Pain Intensity (Visual Analog Scale, VAS) | Baseline, 1 week, 1 month, and 3 months | Pain intensity was assessed using a Visual Analog Scale (VAS) to evaluate changes in pain levels after temporomandibular joint arthrocentesis alone or in combination with intra-articular hyaluronic acid, injectable platelet-rich fibrin (i-PRF), or dextrose prolotherapy. The Visual Analog Scale (VAS) is presented as a 0-10 numeric rating scale, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain severity. |
| Primary | Change in Maximum Mouth Opening | Baseline, 1 week, 1 month, and 3 months | Maximum mouth opening (MMO) was measured clinically in millimeters to evaluate improvement in mandibular mobility after temporomandibular joint arthrocentesis alone or in combination with intra-articular hyaluronic acid, injectable platelet-rich fibrin (i-PRF), or dextrose prolotherapy. |
| Secondary | Change in Jaw Functional Limitation Scale Score (JFLS-8) | Baseline, 1 month, and 3 months (The 1-week assessment was not performed because the questionnaire evaluates symptoms over the preceding month; therefore, a 1-week measurement could cause temporal overlap and affect response interpretation.) | Functional limitation assessed using the 8-item Jaw Functional Limitation Scale (JFLS-8). Each item is scored on a 0-10 numeric rating scale, where 0 indicates no functional limitation and 10 indicates severe functional limitation. Higher scores indicate greater functional impairment. |
| Secondary | Change in Graded Chronic Pain Scale Score (GCPS 2.0) | Baseline, 1 month, and 3 months (The 1-week assessment was not performed because the questionnaire evaluates symptoms over the preceding month; therefore, a 1-week measurement could cause temporal overlap and affect response interpretation.) | Pain-related disability assessed using the Graded Chronic Pain Scale version 2.0 (GCPS 2.0). The scale evaluates chronic pain intensity and pain-related disability. Higher scores represent greater pain severity and functional disability. |
| Secondary | Change in Pain Drawing Score | Baseline, 1 week, 1 month, and 3 months | Pain distribution assessed using the Pain Drawing Questionnaire, where patients mark painful areas on a standardized body diagram. Larger marked areas indicate wider pain distribution. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07479693
GET https://conductscience.org/api/trials/v1/NCT07479693/registered